More takeovers: Eurofins buys pharma QC services firm Sinensis Life Science

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology

More takeovers: Eurofins buys pharma QC services firm Sinensis Life Science
Eurofins Scientific has bought drug quality control testing firm Sinensis Life Science BV in a move designed to expand its global reach.

The deal – financial terms of which were not provided – will see the Dutch contract analysis firm join Eurofins network, which includes the biopharmaceutical reference laboratory Eurofins Lancaster.

Eurofins said the acquisition “acquisition strengthens the Group's geographical footprint​” and will help it "accelerate the deployment of the most advanced testing methodologies to support the pharmaceutical and biotechnology industries across the entire drug development cycle in Europe.​”

The Sinensis group consists of several separate branded services firms, namely: Microsafe Laboratories; Bactimm; ProBase Pharma; Farmalyse; Proxy Laboratories; Prolepha Lab; and Spinnovation​ Analytical BV.

The organisation expects to record revenues in excess of €13.5m ($14.6m) for 2015.

M&A strategy

Eurofins’ 2015 was defined by its M&A activity, the majority of which was pharma industry related.

In June last year Eurofins announced it would pay $40m (Eur35m) for a 75% stake in Emory Genetics Laboratory (EGL) – a specialist provider of genetic testing service – in a deal with current owner Emory University's School of Medicine.

A week earlier the firm bought French testing services firm Biomnis from Bio Alfras SAS for €220m ($249m) and two weeks after it announced a €150m investment in lab group BioAccess.

A month before that Eurofins acquired US-based testing services specialist Diatherix Laboratories.

Prior to these deals, Eurofins bought ViraCor-IBT Laboratories, a provider of biomarker analysis services, and six months after it acquired Boston Heart Diagnostics Corporation from Bain Capital Ventures for $140m.

Related news

Show more

Related products